The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Lp(a) Levels and Atherosclerotic Vascular Disease in a Sample of Patients With Familial Hypercholesterolemia Sharing the Same Gene Defect
Abstract
Abstract There is considerable variation in the severity of cardiovascular disease among patients with familial hypercholesterolemia (FH). Some reports have suggested that plasma lipoprotein(a) [Lp(a)] levels may explain such variation and that FH subjects deficient in LDL receptors, especially those with coronary heart disease, tend to have elevated Lp(a) levels. We have investigated the possible role of the LDL receptor in determining plasma Lp(a) levels in a genetically homogeneous FH population and the contribution of Lp(a) to cardiovascular risk. A total of 98 FH subjects and 66 healthy first- and second-degree relatives from 30 families with FH due to the French-Canadian >10-kilobase deletion of the LDL receptor gene were studied. A reference group of 392 normolipidemic French-Canadian participants in a Heart Health Survey was used for comparison. FH subjects were subdivided into subsets of 63 individuals free from atherosclerotic vascular disease (AVD) and 35 individuals with AVD. A complete cardiovascular evaluation was performed, and plasma lipid, lipoprotein, and Lp(a) levels were measured in all subjects in the absence of medication. Apolipoprotein (a) [apo(a)] phenotype was determined in 112 of FH and non-FH subjects. The log-transformed values for plasma Lp(a) were not significantly different among the three groups: 0.98±0.54 (mean±SD) in FH subjects with AVD, 0.89±0.51 in FH subjects without AVD, and 0.82±0.64 in their relatives. The distribution of the apo(a) phenotypes did not differ between the FH and non-FH groups. Comparison of two age- and sex-matched subgroups of FH subjects, with and without AVD, failed to show any differences in Lp(a) level. However, mean Lp(a) log values in the reference group (n=392) were significantly lower than values obtained for the total FH group (0.79±0.57 versus 0.92±0.52, respectively;P<.05) but were not different from those of the unaffected family members. Thus, in our sample, the LDL receptor appears not to influence plasma Lp(a) levels; rather, these levels reflect shared apo(a) genes. The cardiovascular risk in this group of subjects with FH was related to age, male sex, total and LDL cholesterol, and higher apoB but not Lp(a) levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other studies of individuals with Familial Hypercholesterolemia have not reported an increase in Lp(a) levels.
“Some studies of individuals with Familial Hypercholesterolemia (FH) have reported an increase in Lp(a) levels40-42, but others have not43-45 and suggested that the former may have been confounded by diagnostic ascertainment bias and/or unequal distributions of LPA risk alleles between FH and non-FH populations44,45.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [43]
Citations
Cites
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Schaefer, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510370051031 · Cited by 487
Flagged first, then by citations
Research works printed but not linked: 52
- 10.1161/01.CIR.74.4.758 · DOI
- 10.1001/jama.1986.03380180102027 · DOI
- 10.1161/01.ATV.8.4.398 · DOI
- 10.1016/0002-9149(91)90862-F · DOI
- 10.1161/str.17.5.2945294 · DOI
- 10.1161/01.ATV.9.5.593 · DOI
- 10.1016/0140-6736(92)92756-6 · DOI
- 10.1111/j.1365-2796.1992.tb00596.x · DOI
- 10.1016/0021-9150(93)90179-X · DOI
- 10.1161/circ.86.2.1386292 · DOI
- 10.1016/0014-5793(83)80182-3 · DOI
- 10.1126/science.2530631 · DOI · Paper page
- 10.1172/JCI114625 · DOI
- 10.1172/JCI115855 · DOI
- 10.1016/0021-9150(82)90053-3 · DOI
- Brewer HB Jr. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In: Scanu AM ed. Lipoprotein(a) . New York NY: Academic Press Inc; 1990:211-220. · DOI
- 1985, J Lipid Res, 26, 1314, 10.1016/S0022-2275(20)34257-7 · DOI
- 10.1172/JCI114602 · DOI · Paper page
- 10.1007/BF01745519 · DOI
- 10.1016/0140-6736(90)91242-3 · DOI
- 10.1172/JCI110896 · DOI · Paper page
- 10.1073/pnas.86.11.4171 · DOI
- 10.1016/S0140-6736(88)92884-X · DOI
- 10.1161/atv91.11.4.1829633 · DOI
- 10.1056/NEJM199005243222104 · DOI
- 10.1172/JCI115329 · DOI
- 10.1016/0026-0495(92)90163-5 · DOI
- 10.1056/NEJM198709173171204 · DOI
- Santé Québec. Et votre coeur ça va? Rapport de l’Enquête québécoise sur la santé cardiovasculaire 1990. Montréal Canada: Ministère de la Santé et des Services Sociaux Gouvernement du Québec; 1994:159.
- Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis . Washington DC: US Dept of Health Education and Welfare; 1974;1:1-81. US Dept of Health Education and Welfare publication NIH 75-628.
- 10.1161/01.ATV.5.6.639 · DOI
- 1989, Clin Genet, 36, 219, 10.1111/j.1399-0004.1989.tb03194.x · DOI
- 10.1172/JCI116370 · DOI
- 10.1016/0021-9150(91)90111-F · DOI
- 1990, J Lipid Res, 31, 1247, 10.1016/S0022-2275(20)42633-1 · DOI
- 10.1016/0021-9150(92)90279-P · DOI
- 10.1172/JCI117794 · DOI · Paper page
- 1993, J Biol Chem, 268, 8569, 10.1016/S0021-9258(18)52913-6 · DOI
- 10.1161/atv91.12.10.1390593 · DOI
- 10.1161/atv91.14.10.7918305 · DOI
- 1991, J Lipid Res, 32, 1513, 10.1016/S0022-2275(20)41918-2 · DOI
- 1991, Clin Invest Med, 14, 146
- 1991, Atherosclerosis Rev, 23, 63
- 10.1161/circ.92.3.290 · DOI
- 10.1016/0021-9150(91)90007-P · DOI
- 10.1016/0021-9150(93)90054-X · DOI
- 10.1001/jama.1993.03510180065035 · DOI
- 10.1111/j.1365-2362.1994.tb02373.x · DOI
- 10.1161/atv91.14.11.7947596 · DOI
- 1994, Clin Genet, 46, 42, 10.1111/j.1399-0004.1994.tb04200.x · DOI
- 10.1093/clinchem/39.7.1382 · DOI
- Naruszewicz M Giroux LM Davignon J. Oxidative modification of lipoprotein(a) causes changes in the structure and biological properties of apo(a). Chem Phys Lipids . 1994;67/68:167-174. · DOI
Cited by
Sorted by citations
Nordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
Hepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems
Kiss, I., Neuwert, N., Oberle, R., Hengstschläger, M., Osmanagic-Myers, S., & Stangl, H. (2025) · Biomolecules · doi:10.3390/biom15070956 · Cited by 11
Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening
Khan, T. G., Bragazzi Cunha, J., Raut, C., Burroughs, M., Vyas, H. S., Leix, K., Goonewardena, S. N., Smrcka, A. V., Speliotes, E. K., & Emmer, B. T. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119174 · Cited by 6
Metadata
- Authors
- Carmena, R., Lussier-Cacan, S., Roy, M., Minnich, A., Lingenhel, A., Kronenberg, F., & Davignon, J.
- Affiliations
- From the Endocrine Service, Hospital Clinico Universitario, Valencia, Spain (R.C.); the Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Quebec, Canada (S.L.-C., M.R., A.M., J.D.); and the Institute for Medical Biology and Genetics, University of Innsbruck, Innsbruck, Austria (A.L., F.K.).
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1996-01
- Volume
- 16
- Issue
- 1
- Pages
- 129-136
- ISSN
- 1079-5642
- 1524-4636
- Cited by
- 31
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review